Loading...
SeqLL Inc.
SQL•NASDAQ
Healthcare
Medical - Diagnostics & Research
$6.60
$-0.16(-2.38%)

Over the last four quarters, SeqLL Inc. achieved steady financial progress, growing revenue from $78659.00 in Q4 2022 to $0.00 in Q3 2023. Gross profit stayed firm with margins at N/A in Q3 2023 versus 99% in Q4 2022. Operating income totaled -$1.29M in Q3 2023, maintaining a N/A margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$1.25M. Net income rose to -$1.27M, with EPS at -$3.33. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan